Cargando…
Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated mo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362976/ https://www.ncbi.nlm.nih.gov/pubmed/35945226 http://dx.doi.org/10.1038/s41467-022-32149-8 |
_version_ | 1784764828079882240 |
---|---|
author | Pardi, Norbert Carreño, Juan Manuel O’Dell, George Tan, Jessica Bajusz, Csaba Muramatsu, Hiromi Rijnink, Willemijn Strohmeier, Shirin Loganathan, Madhumathi Bielak, Dominika Sung, Molly M. H. Tam, Ying K. Krammer, Florian McMahon, Meagan |
author_facet | Pardi, Norbert Carreño, Juan Manuel O’Dell, George Tan, Jessica Bajusz, Csaba Muramatsu, Hiromi Rijnink, Willemijn Strohmeier, Shirin Loganathan, Madhumathi Bielak, Dominika Sung, Molly M. H. Tam, Ying K. Krammer, Florian McMahon, Meagan |
author_sort | Pardi, Norbert |
collection | PubMed |
description | Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates. |
format | Online Article Text |
id | pubmed-9362976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93629762022-08-10 Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses Pardi, Norbert Carreño, Juan Manuel O’Dell, George Tan, Jessica Bajusz, Csaba Muramatsu, Hiromi Rijnink, Willemijn Strohmeier, Shirin Loganathan, Madhumathi Bielak, Dominika Sung, Molly M. H. Tam, Ying K. Krammer, Florian McMahon, Meagan Nat Commun Article Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates. Nature Publishing Group UK 2022-08-09 /pmc/articles/PMC9362976/ /pubmed/35945226 http://dx.doi.org/10.1038/s41467-022-32149-8 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pardi, Norbert Carreño, Juan Manuel O’Dell, George Tan, Jessica Bajusz, Csaba Muramatsu, Hiromi Rijnink, Willemijn Strohmeier, Shirin Loganathan, Madhumathi Bielak, Dominika Sung, Molly M. H. Tam, Ying K. Krammer, Florian McMahon, Meagan Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title | Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title_full | Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title_fullStr | Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title_full_unstemmed | Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title_short | Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses |
title_sort | development of a pentavalent broadly protective nucleoside-modified mrna vaccine against influenza b viruses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362976/ https://www.ncbi.nlm.nih.gov/pubmed/35945226 http://dx.doi.org/10.1038/s41467-022-32149-8 |
work_keys_str_mv | AT pardinorbert developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT carrenojuanmanuel developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT odellgeorge developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT tanjessica developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT bajuszcsaba developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT muramatsuhiromi developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT rijninkwillemijn developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT strohmeiershirin developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT loganathanmadhumathi developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT bielakdominika developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT sungmollymh developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT tamyingk developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT krammerflorian developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses AT mcmahonmeagan developmentofapentavalentbroadlyprotectivenucleosidemodifiedmrnavaccineagainstinfluenzabviruses |